SCHEMBL6028360

SCHEMBL6028360

O=C(Nc1ccc(-c2ncc(-c3ccc(NC(=O)C4CCCCC4)cc3)[nH]2)cc1)C1CCCCCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.62
PTPN2 P17706 1/20 0.61
HPGD P15428 3/20 0.51
SCN3A Q9NY46 2/20 0.51
SCN9A Q15858 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
KDM4E B2RXH2 4/20 0.47
TP53 P04637 1/20 0.47
KIT P10721 1/20 0.47
KDR P35968 1/20 0.47
FLT3 P36888 1/20 0.47
ALDH1A1 P00352 3/20 0.46
HSD17B10 Q99714 2/20 0.46
NR2E3 Q9Y5X4 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPK1 P28482 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14305032 1.00 PTPN1 (0.62) PTPN1PTPN2HPGDSCN3ASCN9A
SCHEMBL6028790 1.00 PTPN1 (0.62) PTPN1PTPN2HPGDSCN3ASCN9A
SCHEMBL14311202 1.00 PTPN1 (0.62) PTPN1PTPN2HPGDSCN3ASCN9A
SCHEMBL6029160 0.93 PTPN1 (0.54) PTPN1PTPN2HPGDSCN3ASCN9A
SCHEMBL6028319 0.93 PTPN1 (0.54) PTPN1PTPN2HPGDSCN3ASCN9A
SCHEMBL6028361 0.93 PTPN1 (0.54) PTPN1PTPN2HPGDSCN3ASCN9A
SCHEMBL6887046 0.93 PTPN1 (0.54) PTPN1PTPN2HPGDSCN3ASCN9A
SCHEMBL6887198 0.93 PTPN1 (0.54) PTPN1PTPN2HPGDSCN3ASCN9A
SCHEMBL6026306 0.92 HPGD (0.56) PTPN1PTPN2HPGDSCN3ASCN9A
SCHEMBL6026276 0.91 PTPN1 (0.52) PTPN1PTPN2HPGDSCN3ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1613310-A1 IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS Avanir Pharmaceuticals (US) 2006-01-11 EP disclosed
US-20040229927-A1 Imidazole derivatives for treatment of allergic and hyperproliferative disorders AVANIR PHARMACEUTICALS 2004-11-18 US disclosed
WO-2004091610-A1 IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS AVANIR PHARMACEUTICALS (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229927-A1 Imidazole derivatives for treatment of allergic and hyperproliferative disorders ICOS, TSLP, IKZF3 PTPN1 2513/4885PTPN2 2100/4885HPGD 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.